Authors: William Curatolo James A Nightingale Scott M Herbig
Publish Date: 2009/03/10
Volume: 26, Issue: 6, Pages: 1419-1431
Abstract
A variety of small and polymeric molecules were screened for their ability to inhibit drug precipitation in supersaturated solutions The best polymeric materials were utilized to create spraydried dispersions SDDs of drug and polymer and these were tested for drug form and homogeneity Dispersions were tested in vitro for their ability to achieve and maintain drug supersaturation for a variety of drug structuresOf the 41 materials tested HPMCAS was the most effective at maintaining drug supersaturation Drug/HPMCAS SDDs were consistently more effective at achieving and maintaining drug supersaturation in vitro than were SDDs prepared with other polymers Drug/HPMCAS SDDs were effective in vitro for eight low solubility drugs of widely varying structure Drug/HPMCAS SDDs were more effective at achieving and maintaining supersaturation than were rotoevaporated Drug/HPMCAS dispersions or physical mixtures of Drug and HPMCAS The degree of achievable drug supersaturation increased with increasing polymer content in the SDD The drug in Drug /HPMCAS SDDs was amorphous and the dispersions were demonstrated to have a single glass transition and were thus homogeneousThe following colleagues did much of the initial work on screening and on development of HPMCAS SDDs including many of the formulations included in this paper at Bend Research Doug Lorenz Gina Lorenz Christi Hostetler and Kathy Colombo Pugh Initial spray drying apparatus development was done at Bend Research by Christi Hostetler and Doug Millard We thank Karen Lillebo Alison Viles Ann Patten and Holly Neighbarger of Bend Research for the dissolution tests We are indebted to Scott McCray of Bend Research for assembling and organizing much of the data in this paper We are pleased to acknowledge many helpful discussions with Dwayne Friesen and Chris Babcock of Bend Research and Ravi Shanker of Pfizer We gratefully acknowledge the enthusiastic support of David Dresback and Timothy Hagen of Pfizer
Keywords: